This post has been archived and contains information that may be out of date.
The U.S. Food and Drug Administration (FDA) has authorized the emergency use of the Pfizer-BioNTech COVID-19 vaccine for children ages 5 through 11.
The Pfizer-BioNTech COVID-19 vaccine for children in this age group is administered as a two-dose primary series, three weeks apart, but is a lower dose (10 micrograms) than that used for ages 12 older (30 micrograms).
The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices will meet on Nov. 2 to provide recommendations on the pediatric COVID-19 vaccine, prior to formal authorization by the CDC director.
